BMS, Synairgen Regroup After Trials Miss Primary Endpoints

Bristol Myers Squibb shared the news today that its Phase-III clinical trial investigating the safety and efficacy of Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy (NCT03036098) in patients with metastatic urothelial carcinoma, failed to meet the predetermined primary endpoint. The endpoint measured the overall survival in patients that demonstrated ≥1% PD-L1 expression at the time of final analysis. All data is held in comparison to the current standard of care, which is chemotherapy alone.